Medtech Rises To Challenge Of Meeting Infinite Heath Care Demand With Finite Resources
The relative absence of blockbuster M&A within medtech in 2018, compared with recent years, does not mean that consolidation of the industry – and of providers and payers – will not continue apace in 2019 and beyond. In fact, it is written – if not in the stars then possibly in digital coding – that there will be fewer and bigger entities at the top end of the ecosystem of medtech stakeholders. And rising demand will be met more and more by digital tools and functionalities.
You may also be interested in...
US medtech industry association AdvaMed issued a statement on Nov. 25 in reaction to recently published claims from a group of investigative reporters seeking to highlight what is wrong with the medical technology industry and what drives global innovators. The group, the International Consortium of Investigative Journalists (ICIJ), says it polled 250 journalists from around the world in a bid to assess how devices are tested, approved, marketed and monitored. Is their work balanced and fair, In Vivo asks?
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.
Boston Scientific Corp. has been back on the M&A trail in a big way in 2018, with a succession of strategic additions of various sizes that all have potential patient and shareholder impact across – and beyond – its established divisions. Chief medical officer of 18 months Ian Meredith explains the thought processes driving this policy, and the added dimension a CMO can bring to the overall question of strategy.